PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (...
January 18 2018 - 1:11AM
REGULATED INFORMATION
GHENT, Belgium, 18 January 2018 -
Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced,
in accordance with Article 14 of the Belgian Law of 2 May 2007
regarding the publication of major shareholdings in issuers whose
securities are admitted to trading on a regulated market (the
"Transparency Law"), that it received a notification of
shareholdings from FMR LLC on 16 and 17 January 2018.
FMR LLC (taking into account the holdings of its
subsidiary undertakings) now holds a total of 7,230,164 voting
securities of Ablynx, representing 9.68% of the current 74,720,644
outstanding voting rights of Ablynx (versus 9.50% notified
previously on 25 August 2017).
FMR LLC has notified Ablynx that FMR Co., Inc.,
a subsidiary of Fidelity Management & Research Company, which
itself is a subsidiary of FMR LLC (the ultimate parent company) has
downward crossed the 5% threshold of voting rights of Ablynx since
15 January 2018 and upward crossed the 3% threshold of voting
rights held through financial instruments since 16 January
2018.
The notification contains the following
information:
- Reason for the notification:
- acquisition or disposal of voting securities or voting
rights
- acquisition or disposal of financial instruments that are
treated as voting securities
- Notification by: a parent undertaking or a controlling
person
- Persons subject to the notification requirement: FMR
LLC
- Transaction date: 15 and 16 January 2018
- Threshold that is crossed: 5% of voting rights and 3% of
voting rights held through financial instruments
- Denominator: 74,720,644
- Details of the notification:
Name of select subsidiaries of FMR LLC |
% of voting rights |
% of voting rights held through financial instruments* |
Total of both |
FMR LLCFidelity Management & Research CompanyFMR Co., Inc. |
4.41% |
3.21% |
7.62% |
FMR LLCFIAM Holdings Corp.Fidelity Institutional Asset Management
Trust Company |
1.05% |
|
1.05% |
FMR LLCFIAM Holdings Corp.FIAM LLC |
1.02% |
|
1.02% |
TOTAL |
6.47% |
3.21% |
9.68% |
* Type of financial instrument: "Right of Recall
- Chain of controlled undertakings through which the holding
is effectively being held: The holdings attributable to FMR LLC
arise from holdings of various undertakings for collective
investment that are managed by FMR Co., Inc., Fidelity
Institutional Asset Management Trust Company and FIAM LLC, each of
which are entities that are subsidiaries of, and controlled by, FMR
LLC. These undertakings for collective investment have granted FMR
LLC discretionary power to vote the securities in accordance with
the FMR LLC board proxy voting policy. FMR LLC is not a controlled
undertaking.
More information is available in the
transparency notification. Full versions of both transparency
notifications are available on Ablynx website, under the section
Investors.
The articles of the association of Ablynx NV
provide for shareholders notification threshold of 3%, 5% or a
multiple of 5% of the total number of existing voting rights.
About Ablynx
Ablynx is a biopharmaceutical company engaged in
the development of Nanobodies®, proprietary therapeutic proteins
based on single-domain antibody fragments, which combine the
advantages of conventional antibody drugs with some of the features
of small-molecule drugs. Ablynx is dedicated to creating new
medicines which will make a real difference to society. Today, the
Company has more than 45 proprietary and partnered programmes in
development in various therapeutic areas including inflammation,
haematology, immuno-oncology, oncology and respiratory disease. The
Company has collaborations with multiple pharmaceutical companies
including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck &
Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo
Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is
headquartered in Ghent, Belgium. More information can be found on
www.ablynx.com.
For more information, please
contactAblynx:Dr Edwin MosesCEOt: +32 (0)9
262 00 07m: +32 (0)473 39 50 68e: edwin.moses@ablynx.com
Lies VannesteDirector Investor Relationst: +32 (0)9
262 01 37m: +32 (0)498 05 35 79 e:
lies.vanneste@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media relations:Consilium Strategic
CommunicationsMary-Jane Elliott, Philippa Gardner, Sukaina
Virjit: +44 (0)20 3709 5700e:
ablynx@consilium-comms.com
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/a4bc18a9-2759-4332-8305-62134c6818cf